Intended for healthcare professionals

Feature Diabetes Drugs

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3680 (Published 09 June 2013) Cite this as: BMJ 2013;346:f3680

Re: Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

This is a valid scientific question that is being assessed in the medical literature and apparently by the FDA and European Medicines Agency. The diabetes community is in the inter-regnum between the launch of a new class of drugs and hard end-point data that will clarify the risk:benefit ratios in different classes of patients.

However I really think the style of this article is not appropriate. The tone is that of a detective investigating a conspiracy which includes the regulators. Thus meetings are repeatedly described as 'closed door'.

BMJ should have a different style to Despatches.

Competing interests: No competing interests

18 June 2013
Simon W. Coppack
Consultant Diabetes
Barts Health
Blizard Institute, Barts & The London School of Medicine